FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
AdComnegativeNegative
AI Analysis
Summary
The FDA rejected Replimune's Phase 3 melanoma trial data package as 'not interpretable,' likely requiring an advisory committee review. This regulatory setback mirrors similar FDA concerns raised about Capricor's DMD cell therapy program.
Clinical Trial Data
Phase
Phase_3
Outcome Details
FDA called Phase 3 melanoma data package 'not interpretable,' setting up advisory committee meeting
Importance:8/10
Sentiment:
-0.80
FDAmelanomaPhase 3data qualityadvisory committeeregulatory setback
Read the original article
Published by BioSpace on July 28, 2026 1:13 PM